[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611385":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":18,"locations":24,"responsibleParty":43,"collaborators":45,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":11,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":11,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":27,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Regend Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Airway Basal Stem Cells","EXPERIMENTAL",null,[13],"Biological: Airway Basal Stem Cells",[15],{"type":16,"name":9,"description":9,"armGroupLabels":17,"otherNames":11},"BIOLOGICAL",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":11,"email":23},"Liling Qian, Professor and Chief Physician","CONTACT","086-021-62474880","qianliling@shchildren.com.cn",[25],{"facility":26,"status":27,"city":28,"state":11,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University","RECRUITING","Shanghai","200000","China","CN",{"type":33,"coordinates":34},"Point",[35,36],121.45806,31.22222,{"lat":36,"lon":35},[39],{"name":40,"role":21,"phone":41,"phoneExt":11,"email":42},"Lei He","086-021-52976581","hl@shchildren.com.cn",{"type":44,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[46],{"name":47,"class":48},"Shanghai Children's Hospital","OTHER","100611385","early-phase-1-treatment-of-pediatric-bronchiolitis-obliterans-by-airway-basal-stem-cells-100611385",false,"NCT07239895","Treatment of Pediatric Bronchiolitis Obliterans by Airway Basal Stem Cells","Exploratory Study of Airway Basal Stem Cells on Treatment of Pediatric Bronchiolitis Obliterans","Inclusion Criteria:\n\n* Males and females, aged between 28 days and 18 years;\n* Diagnosed with bronchiolitis obliterans according to the guidelines;\n* Meeting at least one of the following: FEV1 \\\u003C 55% of predicted value; requiring continuous assisted mechanical ventilation or oxygen therapy;\n* None of acute infections within the past four weeks;\n* Tolerating bronchoscopy;\n* The child and\u002For parent(s) provide informed consent, and are able to understand and adhere to scheduled visits, treatments, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* Subjects with bronchiolitis obliterans syndrome (BOS) who are on a current cGVHD treatment regimen at screening.\n* At the time of screening, subject who is positive in each of treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody test. Hepatitis B virus carriers with stable current condition can be enrolled. Cured hepatitis C patients with negative result in HCV ribonucleic acid (RNA) test can be enrolled as well.\n* Subject who is assessed to have major lung diseases other than BO by investigators at screening or who has other severe systemic diseases within 6 months prior to screening and is considered to be unsuitable for this study by investigators.\n* Presence of severe coagulation dysfunction at screening and may compromise the safety of bronchoscopy in the investigator's judgment.\n* Subjects requiring long-term maintenance anticoagulant therapy or antiplatelet aggregation therapy, and for whom, in the investigator's assessment, the medication cannot be discontinued within a week prior to cell collection and infusion.\n* Subjects with suicide risk or a history of psychiatric disorders at screening.\n* Participation in another interventional clinical study within 3 months prior to screening.\n* Poor compliance, making him or her difficult to complete the study.\n* Subjects who is considered to be unsuitable for this study in in the opinion of the investigator.","ALL","28 Days","18 Years",{"count":60,"type":61},12,"ESTIMATED","INTERVENTIONAL",[64],"EARLY_PHASE1","Bronchiolitis obliterans (BO) is a chronic lung disease which was initiated with injury of the bronchiolar epithelium and resulted in nonuniform luminal obliteration or narrowing. Among children, the most common form of BO is post-infectious BO with a lack of treatment guidelines or standard therapy. In this study, an open, single-armed study is performed to preliminarily evaluate the safety and efficacy of airway basal stem cells on treatment of pediatric BO.",[67],"Pediatric Bronchiolitis Obliterans",[9,69,70,71],"Bronchiolitis obliterans","Bronchiolar Epithelium","Pedatric Bronchiolitis Obliterans","2026-01-12",{"date":74,"type":75},"2026-01-14","ACTUAL",{"date":77,"type":75},"2025-11-11",{"date":79,"type":61},"2027-11",{"name":5,"class":6},1]